The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study

BACKGROUND: Niraparib is the only poly (adenosine diphosphate-ribose)-polymerase (PARP) inhibitor available as oral monotherapy for maintenance, regardless of BRCA mutational status. METHODS: This phase I, open-label, non-randomized, dose-escalation study was conducted in Japan using a 3 + 3 design....

Descripción completa

Detalles Bibliográficos
Autores principales: Yonemori, Kan, Shimizu, Toshio, Kondo, Shunsuke, Iwasa, Satoru, Koyama, Takafumi, Kitano, Shigehisa, Sato, Jun, Shimomura, Akihiko, Shibaki, Ryota, Suri, Ajit, Kase, Yoichi, Sumino, Shuuji, Tamura, Kenji, Yamamoto, Noboru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086052/
https://www.ncbi.nlm.nih.gov/pubmed/33621324
http://dx.doi.org/10.1093/jjco/hyab013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8086052/
https://www.ncbi.nlm.nih.gov/pubmed/33621324
http://dx.doi.org/10.1093/jjco/hyab013

Ejemplares similares